No association seen for cumulative nonsteroidal anti-inflammatory drug dose with reduced dementia risk<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, March 5, 2025 (HealthDay News) — Long-term nonsteroidal anti-inflammatory drug (NSAID) use is associated with reduced dementia risk, according to a study published online March 5 in the Journal of the American Geriatrics Society<\/em>.<\/p>\n Ilse vom Hofe, from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues examined long-term exposure to NSAID medication in relation to dementia risk in a study of 11,745 dementia-free participants from the prospective population-based Rotterdam Study. NASID use from 1991 was derived from pharmacy dispensing records and was classified into four mutually exclusive categories of cumulative NSAID use: nonuse, short-term use (less than one month), intermediate-term use (one to 24 months), and long-term use (more than 24 months). The association with dementia risk until 2020 was determined.<\/p>\n The researchers found that 81.1 percent of the participants had used NSAIDs at any given time during an average follow-up of 14.5 years; 2,091 participants developed dementia. NSAID use was associated with lower dementia risk for long-term users (hazard ratio, 0.88) and with elevated risk for short-term and intermediate-term use (hazard ratios, 1.04 and 1.04, respectively). There was no association seen for cumulative dose of NSAIDs with reduced dementia risk. Slightly stronger associations were seen for long-term use of NSAIDs without known effects on amyloid-\u03b2 versus amyloid-lowering NSAIDs (hazard ratios, 0.79 versus 0.89, respectively).<\/p>\n “Although our results are an indication of the important role of inflammation in the treatment of dementia, they do not justify the recommendation of long-term treatment with NSAIDs for the prevention of dementia, given its potential adverse effects,” the authors write.<\/p>\n